Speaker Profile
M.D., DABP, Executive Medical Director and Head of Companion Diagnostics, Merck & Co.
Biography
Dr. Emancipator led the Merck team which partnered with Agilent Technologies to develop the 22C3 PD-L1 immunohistochemistry test which identifies those non-small cell lung cancer patients most likely to benefit from Keytruda® (pembrolizumab), which is the first FDA-approved companion diagnostic in cancer immunotherapy, and which enabled Keytruda to become the first immunotherapy to be approved for first-line treatment of lung cancer. He was one of six members of the Keytruda Team to receive the 2015 PhRMA Research and Hope Award for Biopharmaceutical Industry Research on behalf of Merck. His has held positions at National Institutes of Health, Cornell University Medical College, Beth Israel Medical Center (NY), and Bayer Healthcare. He is a former officer of the American Society for Clinical Pathology, and is a regular reviewer for the American Journal of Clinical Pathology. His credits include more than 100 papers and abstracts, and more than 100 extramural presentations.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis:
As immunotherapies becomes a backbone of cancer treatment, biomarker assays will be critical to optimizing the use of immunotherapies as single agent or in combinations. This panel will explore how leading biopharma and academic researchers are identifying biomarkers and developing companion diagnostics for immuno-oncology.
